Molbio Diagnostics Reports Rs 52.7 Crore Q1 Profit Post IPO

Molbio Diagnostics, which recently made its stock market debut, reported a profit of Rs 52.74 crore for the first quarter ending June 2026. This marks a significant turnaround from the Rs 23.94 crore loss the company experienced during the same period last year. The surge in profit is attributed to the robust sales of the company's Truenat test-kits, as revealed in a regulatory filing.

Strong Financial Performance Following IPO

The Goa-based diagnostics firm successfully raised approximately Rs 940 crore through its Initial Public Offering (IPO) and was listed on the stock exchanges on August 17. The company's total income for the first quarter reached Rs 411.48 crore, a substantial increase from Rs 100.47 crore in Q1 of the previous fiscal year. This growth was largely driven by a surge in the volume of Truenat test-kit sales, which expanded to 62.4 lakh units from just 7.9 lakh units in the corresponding quarter last year.

Truenat Test-Kit: A Key Growth Driver

Truenat, Molbio's flagship product, is designed to quickly and accurately detect a range of infectious diseases at the point of care, which has significantly contributed to the company's financial turnaround. The increased demand for these test-kits has been pivotal in boosting the company's revenue and profitability. Sriram Natarajan, Executive Director and CEO of Molbio Diagnostics, expressed optimism about the company's future, stating that FY27 is a milestone year for Molbio as it transitions to a publicly listed entity with strong growth indicators.

Future Outlook

The successful IPO and subsequent financial performance indicate a positive trajectory for Molbio Diagnostics. The company's ability to capitalize on its innovative diagnostic solutions, particularly the Truenat test-kit, positions it well for future growth. As the healthcare sector continues to expand, Molbio's performance in the upcoming quarters will be closely watched by investors and industry analysts alike.